Key points are not available for this paper at this time.
Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.
Nadal et al. (Mon,) studied this question.